PROGRAM LEADERS---PEDIATRIC CANCER

儿科癌症计划的主要目标是：1)通过对这些疾病的全面分子、蛋白质组和基因组分析，增加对儿科恶性肿瘤生物学的了解；2)利用这些研究提供的信息改进儿科癌症的诊断、预后和治疗方法；3)确定可用于治疗的新的分子靶点；4)研究选定的儿科癌症的遗传易感性；5)确定有效的治疗方法并进行创新的第一阶段和第二阶段试验；以及6)研究儿童癌症治疗的远期效应和改善幸存者的预后。该计划还指导和培训儿科肿瘤学研究员和NCI资助的研究生临床研究实习生。儿科项目位于德克萨斯州儿童医院，是全国最大的儿科癌症项目之一。每年约有550名新的儿科癌症患者。儿科项目负责人是David Poplack医学博士；联合负责人是医学博士刘清。儿科项目有23名研究成员、22名成员和25名临床研究人员，他们来自贝勒医学院(包括儿科、外科、神经外科、放射科)的不同部门。 治疗、眼科和病理学)和莱斯大学生物工程系。去年，该计划得到了NCI的3,734,599美元的支持和7,673,535美元的同行审查资金。该计划的成员在同行评议的期刊上发表了230篇与癌症有关的文章，其中53%是计划内合作，27%是计划间合作。 儿科计划的主要研究主题包括：1)儿科实体肿瘤的生物学和治疗研究，2)儿科癌症发展疗法，3)儿科脑瘤研究。儿科计划是美国最活跃的儿科癌症研究计划之一。该计划有221个IRB批准的癌症相关方案。其中128项是临床试验，其中25项是由儿科项目调查人员开发的。该计划通过其与NCI支持的儿童肿瘤学小组、儿童脑瘤联盟和神经母细胞瘤治疗网络的新进展的正式联系进行了大量的临床试验。临床研究在德克萨斯儿童医院的门诊和住院设施中进行。 开展了许多方案间和方案内以及机构间的合作，以加强实验室和临床研究方案。定期的互动式和指导性会议是方案内外科学知识交流的组成部分。儿科计划在地方、地区、国家和国际层面开展重要的外展活动。

The major goals of the Pediatric Cancer Program are: 1) to increase understanding of the biology of pediatric malignancies through comprehensive molecular, proteomic and genomic analysis of these diseases, 2) to use information from these studies to improve diagnostic, prognostic and therapeutic approaches for pediatric cancers, 3) to identify novel molecular targets that may be exploited therapeutically, 4) to study the genetic pre-disposition for selected pediatric cancers, 5) to identify effective therapies and conduct innovative Phase I and Phase II trials, and 6) to study the late effects of childhood cancer therapy and improve outcomes of survivors. The Program also mentors and trains pediatric oncology fellows and NCI-funded post-fellowship clinical research trainees. The Pediatric Program is located at Texas Children's Hospital and is one of the largest pediatric cancer programs in the nation. Approximately 550 new pediatric cancer patients are seen each year. The Pediatric Program Leader is David Poplack, M.D.; the Co-Leader is Ching Lau, M.D, Ph.D. The Pediatric Program has 23 Research Members, 22 Members and 25 Clinical Investigators from a variety of Departments at Baylor College of Medicine (including Pediatrics, Surgery, Neurosurgery, Radiation Therapy, Ophthalmology, and Pathology) and from the Bio-Engineering Department at Rice University. Last year, the Program had $3,734,599 in support from the NCI and $7,673,535 in peer-reviewed funding. Members of the program published 230 cancer related publications in peer-reviewed journals of which 53% represented intraprogrammatic collaborations and 27% interprogrammatic collaborations. Major research themes of the Pediatric Program include: 1) biologic and therapeutic studies of pediatric solid tumors, 2) pediatric cancer developmental therapeutics, and 3) pediatric brain tumor research. The Pediatric Program is one of the most active pediatric cancer research programs in the U.S. The Program has 221 IRB approved, cancer related protocols. Of these 128 are clinical trials, 25 of which were developed by Pediatric Program investigators. The Program conducts numerous clinical trials through its formal affiliations with the NCI-supported Children's Oncology Group, Pediatric Brain Tumor Consortium and New Advances in Neuroblastoma Treatment Network. Clinical research is performed in the outpatient and inpatient facilities of Texas Children's Hospital. Numerous inter-and intra-programmatic and inter-institutional collaborations are carried out to enhance both laboratory and clinical research programs. Regular interactive and didactic conferences and meetings are an integral part of the exchange of scientific knowledge within and outside the Program. The Pediatric Program conducts significant outreach activities on a local, regional, national and international level.